Who are Oral administration of Ipragliflozin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NBF, CTM Boost, Insulin/Empaglifozin, SGLT2 inhibitor, Antihyperglycemic Medication, Dapagliflozin (DAPA).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oral-administration-of-ipragliflozin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Oral administration of Ipragliflozin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral administration of Ipragliflozin (Oral administration of Ipragliflozin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor. Area: Diabetes.

marketed SGLT2 inhibitor SGLT2 (sodium-glucose cotransporter 2) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Oral administration of Ipragliflozin (Oral administration of Ipragliflozin) — Asan Medical Center. Ipragliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion to lower blood glucose levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Oral administration of Ipragliflozin TARGET	Oral administration of Ipragliflozin	Asan Medical Center	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
NBF	NBF	Universidad Complutense de Madrid	marketed	SGLT2 inhibitor	SGLT2
CTM Boost	CTM Boost	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	marketed	SGLT2 inhibitor	SGLT2
Insulin/Empaglifozin	Insulin/Empaglifozin	University of Campania Luigi Vanvitelli	marketed	Insulin + SGLT2 inhibitor combination	Insulin receptor; SGLT2 (sodium-glucose cotransporter 2)
SGLT2 inhibitor	SGLT2 inhibitor	University of Minnesota	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
Antihyperglycemic Medication	Antihyperglycemic Medication	Merck Sharp & Dohme LLC	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
Dapagliflozin (DAPA)	Dapagliflozin (DAPA)	Ottawa Heart Institute Research Corporation	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor class)

Daewon Pharmaceutical Co., Ltd. · 13 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 10 drugs in this class
Takeda · 10 drugs in this class
Taejoon Pharmaceutical Co., Ltd. · 9 drugs in this class
Hanmi Pharmaceutical Company Limited · 9 drugs in this class
Addpharma Inc. · 9 drugs in this class
GlaxoSmithKline · 7 drugs in this class
AO GENERIUM · 7 drugs in this class
Merck Sharp & Dohme LLC · 7 drugs in this class
Nobelpharma · 6 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oral administration of Ipragliflozin — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-administration-of-ipragliflozin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab